isr - ISR STOCK NEWS

Isoray, Inc. (NYSE American: ISR) announced that CEO Lori Woods will speak at the Oppenheimer 32nd Annual Healthcare Conference on March 17 at 1:20 p.m. ET. The event will be a virtual fireside chat, with the opportunity for institutional investors to engage in one-on-one and group meetings with CEO Woods and CFO Jonathan Hunt.

A live webcast will be available on Isoray’s Investor Relations page, with an on-demand replay accessible for 90 days post-event.

On March 2, 2022, researchers from the University of Pittsburgh published a study demonstrating the effectiveness of Isoray's Cesium-131 brachytherapy for treating intermediate-risk prostate cancer. The study involved 335 patients and reported biochemical success rates of 97.6% for favorable and 91.4% for unfavorable groups at five years. Notably, the use of Cesium-131 minimized acute toxicity, supporting its growing role in prostate cancer treatment. Isoray's CEO emphasized the significance of these findings for clinical practice, reinforcing the company's position as the sole producer of Cesium-131.

Isoray, Inc. (NYSE AMERICAN: ISR) reported a 19% increase in revenue for Q2 of fiscal 2022, reaching $2.82 million compared to $2.36 million the previous year. Core prostate brachytherapy revenue grew 13%, representing 76% of total revenue. Non-prostate revenue surged 46%, primarily from brain cancer treatments. However, gross profit margin decreased to 43.3% due to rising material costs. Operating expenses rose significantly by 40%, with net loss increasing to $1.60 million from <$b>0.87 million.

Isoray, Inc. (NYSE AMERICAN: ISR) has announced a conference call scheduled for February 8, 2022, at 4:30 p.m. ET to discuss its financial results for Q2 FY 2022, ending December 31, 2021. A press release detailing the financial results will be issued after market close on the same day. Interested parties can join the call by dialing (888) 506-0062 or through the webcast available on their website. This call marks a significant event for the company as it reviews its performance in the medical technology sector, particularly in brachytherapy.

Isoray, Inc. (NYSE AMERICAN: ISR) reported an 8% year-over-year revenue growth to $2.56 million for Q1 fiscal 2022, primarily driven by a 4% increase in prostate brachytherapy revenue, which constituted 77% of total revenue. Non-prostate brachytherapy revenue surged 20% due to sales for brain cancer treatments. However, gross profit decreased by 17% to $1.03 million, with a gross profit margin of 40.1%. Operating expenses rose 69% to $3.30 million, resulting in a net loss of $2.24 million, compared to a loss of $0.71 million in the prior year.

Isoray, Inc. (NYSE AMERICAN: ISR) announced a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its financial results for the first quarter of fiscal 2022, ending September 30, 2021. The financial results will be released after the close of U.S. stock markets on the same day. Interested parties can join the call by dialing (888) 506-0062 or accessing it via webcast. Isoray specializes in Cesium-131 brachytherapy seeds and aims to provide advanced radiation treatment options for various cancers.

The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its latest consensus statement on low dose rate (LDR) prostate brachytherapy. This inclusion is significant as it's the first mention of Cesium-131 in ABS guidelines. The paper indicates that LDR brachytherapy is suitable for low-risk and favorable intermediate-risk prostate cancer. Cesium-131's advantages include the shortest half-life and high energy levels, which allow for faster dosage delivery and quicker recovery for patients. Isoray remains the sole producer of Cesium-131 brachytherapy seeds.

Isoray has announced a rescheduled conference call on September 22, 2021, at 10:00 a.m. ET to discuss financial results for the fourth quarter and fiscal year ended June 30, 2021. Initially planned earlier, the call was postponed due to technical issues with the conference bridge provider. The financial results were already released on September 21, 2021, after market close. Investors can access the call by dialing 888-506-0062, or 973-528-0011 for international callers, with a simultaneous webcast available for broader accessibility.

Isoray, Inc. (ISR) reported a 19% increase in fourth quarter revenue, reaching $2.71 million, compared to $2.28 million the previous year. Non-prostate brachytherapy revenue soared 92%, driven by treatments for brain cancer, while prostate revenue grew 5%, making up 74% of total revenue. Full-year revenue reached a record $10.05 million, a 4% rise from the last fiscal year. Despite a net loss of $1.06 million for the quarter, the company maintains a strong cash position of $63.8 million and plans to expand its market.